Open-Label Extension of EryDex Study IEDAT-04-2022

Summary

This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).

Timeline

Start

2024-12-11

Primary completion

2026-01-30

Completion

2026-01-30

Outcome

Outcome not reported

Stopped: “eDSP development discontinued”

Drugs

Indications